Ablynx

Background

Ablynx was spun-off from the VIB and and Free University of Brussels in 2001.
The IP portfolio derives from more than ten years of research at VIB & VUB.
Gilde was invited as the only investor from the Netherlands to participate in the 1st financing round.
Gilde established a project team of experts and completed its due diligence.
It took 3 months from 1st contact to investment.

Gilde Role Pre-investment

Together with operational partner Dr Hoogenboom and other advisors Gilde completed the technical due diligence in 2 months time.
After a thorough due diligence Gilde concluded that the technology is unique, has breakthrough potential and is protected by a strong IP portfolio.
Gilde’s positive experience with the investor syndicate and confidence in management team, contributed to the investment decision.

Gilde Role Post-investment

Pieter van der Meer joined the Board as observer and participates in various Board committees.
Advised the company in defining its milestones and strategic objectives.
Provided management with an executive level in-road into Novartis to start negotiating a >EUR 100 million collaboration agreement.
Advised in hiring of key personnel and consultants, including Gilde’s Operational Partner Dr Hoogenboom who joined as the CSO.
Introduced Ablynx to VC firms in preparation for 2nd and 3rd round of financing, assisted in negotiation and evaluating term sheets.
Gilde participated in all subsequent financing rounds to maintain a strong position in the company.
Gilde invited institutional investors who made significant investments in the IPO of the company.

Post Investment Developments

Attracted world-class key personnel.
Completed a large out-licensing deal, broad research collaboration and a series of revenue generating collaborations.
Closed two oversubscribed financing rounds both at significant valuation premiums and broadened its shareholders base.
Strengthened the patent portfolio and reinforced its leadership position in nanobodies after positive decision of the European Patent Office.
Secured a manufacturing contract with a top class CMO.
Built a strong diversified product pipeline and generated nanobodies against 12 human disease targets.
Lead programs demonstrated superior efficacy in animal models as compared to marketed blockbuster products.
Ablynx and Boehringer Ingelheim start major global strategic alliance.
Ablynx raises EUR 75 million in successful IPO - largest ever biotech IPO on Euronext